Eolas Therapeutics entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications. EORA was awarded a Blueprint Neurotherapeutics (BPN) grant from the NIH for the development of the program from the preclinical stage through phase I clinical trials. "We are happy to be partnering with AstraZeneca on our EORA program for their scientific, clinical, regulatory, and commercial expertise. Our two companies share a vision for greatly improving the lives of patients affected by addiction and other neurological disorders," said Albert Man, CEO of Eolas Therapeutics.